Navigation Links
Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
Date:11/15/2007

ompton Hospital and Professor of Clinical Cardiology at Imperial College. "The gastrointestinal toxicity from dual antiplatelet therapy can result in patients skipping or stopping their treatment altogether," continued Dr. Fox. "Even a short discontinuation of therapy in patients who have recently had a drug eluting stent inserted can result in a heart attack. Clearly there is a need for a safer treatment option."

Recent clinical trial data documenting these side effects have begun focusing attention on the incidence and significance of bleeding associated with antiplatelet medicines.

"Our goal is to improve the safety and tolerability of antiplatelet therapy by significantly reducing gastrointestinal adverse events, including bleeding, to help patients stay on their intended antiplatelet treatment," said Mark A. Goldsmith, M.D., Ph.D., President and Chief Executive Officer of Cogentus Pharmaceuticals. "We believe CGT-2168 may be a significant advance that will preserve and extend the cardiovascular benefits of antiplatelet therapy."

Phase III trials are the last stage of clinical testing required by the U.S. Food and Drug Administration. Successful Phase III studies allow a company to file a New Drug Application with the FDA for approval to market a new medicine.

Physicians and patients interested in obtaining more information about COGENT should go to http://www.clinicaltrials.gov.

ABOUT COGENTUS

Cogentus Pharmaceuticals, Inc., of Menlo Park, CA, is a privately held specialty pharmaceutical company founded in 2006. Cogentus (http://www.cogentus.net) is committed to becoming a premier developer of innovative, fixed-dose combination prescription medicines serving unmet medical needs that drive significant commercial opportunities.

Plavix(R) is a registered trademark of Sanofi-Aventis.


'/>"/>
SOURCE Cogentus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
6. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
9. Premier Micronutrient Launches Supplement for Hearing Health
10. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
11. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... and BOSTON , May 24, 2013 /PRNewswire/ ... development company, is pleased to announce that it has engaged Mr ... the Company,s business development capabilities in Japan ... 15 years of experience in business development, licensing and alliance management ... Roche Pharma ( Japan ), Nippon Roche and Tanabe ...
(Date:5/23/2013)... DIEGO y PARÍS, 24 de mayo ... VOLC ), un destacado desarrollador y fabricante de ... mejorar la diagnosis y tratamiento de la enfermedad ... preliminares del ensayo ADVISE ( Ad enosine ... E valuation) II durante la sesión de ...
(Date:5/23/2013)... -- Haemonetics Corporation (NYSE: HAE ) announced today that ... will present at The Deutsche Bank 38 th Annual ... on May 29, 2013 at 1:30pm Eastern time.  ... public may access Mr. Lindop,s presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global healthcare ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... Biopure Corporation,(Nasdaq: BPUR ) today ... II coronary,revascularization trial have been published in ... "Proof-of-concept trial to,evaluate haemoglobin based oxygen therapeutics ... and haemodynamic,results." The manuscript was authored by ...
... RIDGEFIELD, Conn., May 14 Results of the ... -- the,world,s largest clinical research study for secondary ... European Stroke Conference in Nice,France. In the study, ... similar (9.0% and 8.8%, respectively; HR 1.01, 95% ...
Cached Medicine Technology:Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 2Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 3PRoFESS(R) Results Announced at XVII European Stroke Conference 2PRoFESS(R) Results Announced at XVII European Stroke Conference 3PRoFESS(R) Results Announced at XVII European Stroke Conference 4PRoFESS(R) Results Announced at XVII European Stroke Conference 5
(Date:5/24/2013)... Alan Mozes HealthDay Reporter , , FRIDAY, May ... Lewis, accomplishments are remarkable. But it was a physical ... the top of her sport. "I was an ... when my scoliosis was diagnosed by my orthopedic surgeon," ... the Scoliosis Research Society and the American Academy of ...
(Date:5/24/2013)... Western University of Health Sciences’ College ... Accreditation” for the next seven years from the American ... “This is a magnificent achievement, and one we expected ... outcomes,” said College of Veterinary Medicine Dean Phillip Nelson, ... the faculty, staff, preceptors, and students that participated in ...
(Date:5/24/2013)... Orlando, Florida (PRWEB) May 24, 2013 KC ... are the Title Sponsors for FreeRide836. Their oldest sons, Kyle ... Mark and Tracey Russell family and several professional kiteboarders. , ... this amazing project. "This has miraculously come together such that ... be able to participate." , 20 kite boarders will meet ...
(Date:5/24/2013)... Mirena IUD lawyers at the Rottenstein Law Group ... more than 59,229 complaints since 2004 from women claiming they ... known as the Mirena IUD.* , Among the most common ... ‘expulsion,’ where the IUD came out on its own. There ... News article. “Abdominal pain is also common, with 3,774 complaints. ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 E-Dentists.com has ... in partnership with JD Media Surge, a leading medical ... The dental SEO analysis service will focus on providing ... the search engines for their competitive keywords. The dental ... website and recommendations based on what their competitors are ...
Breaking Medicine News(10 mins):Health News:Top-Ranked Golfer Beats Scoliosis 2Health News:Top-Ranked Golfer Beats Scoliosis 3Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2
... School of Medicine have discovered that drinking just 500ml ... pressure. The study, published online today in the American ... the treatment of cardiovascular disease. , Lead by Professor ... Barts and The London School of Medicine, and Professor ...
... spending on medical research in Europe should be doubled ... welfare for Europes citizens and to nurture a thriving ... between European institutions in medical research and improved career ... the main recommendations of the European Medical Research Councils ...
... workforce raises serious,concerns, WASHINGTON, Feb. 5 ... strong objections to President,Bush,s FY2009 budget for both ... the FY 2009 budget reflects some poor choices ... setting a hazardous course for,the future., "The ...
... a clue leading researchers at Washington University School of ... approach for Niemann-Pick disease, a rare, deadly neurodegenerative disorder. ... disease, the researchers suggest that chemical compounds could potentially ... machinery. And they believe the approach also could be ...
... ... Xactly Incent on-demand solution, SAN JOSE, Calif., ... performance management, today announced that Volcano,Corporation (Nasdaq: VOLC ... diagnosis and treatment of vascular and structural heart,diseases, has ...
... ATLANTA, Feb. 5 Ingenious Med, leaders in ... practice management,announces record sales, product deployments, partnerships, and ... 2007 sales increased by,81% over 2006. This increase ... a,dramatic increase in IM,s overall profitability., In ...
Cached Medicine News:Health News:Research shows a daily does of beetroot juice can beat high blood pressure 2Health News:Collaboration needed for strengthening medical research in Europe 2Health News:Association of Academic Health Centers Faults Bush's FY 2009 Budget 2Health News:Chemical chaperone could open door to treatment of neurological disorder 2Health News:Chemical chaperone could open door to treatment of neurological disorder 3Health News:Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 2Health News:Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 3Health News:Ingenious Med Reports Record Sales and Client Expansions in 2007 2
... many features that add value to your ... money. Because our MegaPeel microdermabrasion systems are ... maintain, you spend your time treating patients/clients, ... microdermabrasion systems are available in three models ...
... Chromolite™ is a state-of-the-art hair reduction ... system specially designed for use within ... powerful features and economy in a ... the treatment of unwanted hair, photo ...
... of the IPL Quantum DL and the clinically ... deeper vascular lesions. This cost-effective system is gentle, ... or as an upgrade to the IPL Quantum ... conditions including: Leg veins , Larger ...
Disposable. Sterile Suction Tubing....
Medicine Products: